Sana Biotechnology, Inc. Common Stock
SANASana Biotechnology, Inc. focuses on developing regenerative medicine and gene therapy solutions. The company aims to create and deliver engineered cells as medicines for various diseases, utilizing advancements in cell engineering and gene editing technologies to treat conditions with unmet medical needs.
Company News
Sana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.
Stock promoter Eric Jackson highlighted Sana Biotechnology as a potential '100-bagger' stock, citing falling interest rates, cooling inflation, and biotech sector revival as key catalysts.
Quell Therapeutics has formed a Scientific Advisory Board comprising leading experts in immunology, T-regulatory cell biology, and autoimmune diseases to guide its innovative CAR-Treg cell therapy development.
Sana Biotechnology has priced a public offering of 20,895,522 shares at $3.35 per share and pre-funded warrants, expecting to raise approximately $75 million. Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen are joint book-running managers for the offering.
Sana Biotechnology plans to raise approximately $75 million through a public offering of 20,895,522 common shares and pre-funded warrants at $3.35 per share, with Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen as joint book-running managers.
